MicroAlgo Inc. (the "Company" or "MicroAlgo") (NASDAQ: MLGO), today announced that they have developed a set of quantum algorithms for feedforward neural networks, breaking through the performance ...

The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both ...

The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the ...

This recall involves Head Ski Boots with fluorescent yellow components from model years 2016 through 2022 with the model ...

Maker says Otarmeni will be offered for free in the U.S.

First FDA-approved gene therapy for hearing loss targets a rare inherited form of deafness Treatment restored hearing in most ...

AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene therapies for inherited retinal diseases (IRDs) has today announced its participation in the ...

Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the ...

Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the ...

A 2026 informational overview of the ODIN Faraday Bag's EMF signal-blocking shielding design, Faraday cage attenuation ...

A single injection into the inner ear restored functional hearing in 90% of people born deaf because of mutations in the OTOF ...

When the parents of a toddler born profoundly deaf learned their child carried mutations in both copies of the OTOF gene, a ...